Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma.
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial / Ascierto, P.A., Mandalà, M., Ferrucci, P.F., Guidoboni, M., Rutkowski, P., Ferraresi, V., Arance, A., Guida, M., Maiello, E., Gogas, H., Richtig, E., Fierro, M.T., Lebbè, C., Helgadottir, H., Queirolo, P., Spagnolo, F., Tucci, M., Del Vecchio, M., Gonzales Cao, M., Minisini, A.M., et al.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - (2023), pp. 2961-2969. [10.1200/JCO.21.02961]
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Palmieri, GiuseppeInvestigation
;
2023-01-01
Abstract
Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
